Codexis (CDXS) Restructuring Costs (2022 - 2023)

Codexis (CDXS) recorded quarterly Restructuring Costs of $3.1 million in Q3 2023, up 4261.11% quarter-over-quarter from $72000.0 in Q2 2023.

Codexis (CDXS) Restructuring Costs (2022 - 2023) Analysis & Trends

Codexis' Restructuring Costs history runs 2 years deep, the most recent figure standing at $3.1 million for Q3 2023.

In Q3 2023, Restructuring Costs changed N/A year-over-year to $3.1 million; the TTM figure through Jun 2024 stood at $3.1 million (down 5.16% YoY), while the FY2025 annual figure was $3.4 million, changed N/A from the prior year.
Restructuring Costs was $3.1 million for Q3 2023 at Codexis, up from $72000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $3.2 million in Q4 2022 to a low of $72000.0 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Codexis	236.00 Mn	170.86 Mn	13.18 Mn

Download Data